Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MESA Chemotherapy for NK/T Cell Lymphoma
NCT01933282Phase 2Unknown
- Sponsor
- Air Force Medical University
- Start
- Jan 2013
- Primary completion
- Jan 2015
- Modality
- Therapeutic Enzymes, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of methotrexate, etoposide, dexamethasone and pegaspargase in Extranodal NK/T-cell lymphoma (ENKTL), sponsored by Air Force Medical University. Primary endpoint: Complete Remission at 24 weeks. Status: unknown.
02
Drugs
methotrexateetoposidedexamethasonepegaspargase
03
Conditions
Extranodal NK/T-cell lymphoma (ENKTL)
Beyond the preview
Go deeper on NCT01933282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01933282.